文献速递预防保健、筛查与疫苗慢病管理基层心理健康

质量改进项目:提升男性丙戊酸患者对家庭计划风险的认知

Quality improvement project improving awareness of family planning risks with valproate in male patients.
PubMed 文献 · Br J Gen Pract · 2026-05-14

该质量改进项目针对全科诊所22名使用丙戊酸的男性患者,通过短信和电话传达MHRA关于男性围受孕期丙戊酸使用可能与子代神经发育障碍相关的指导。结果显示短信单独效果有限,仅1人回复;电话成功联系18人,其中13人通过电话获知信息,但无患者采取避孕等进一步行动。

要点

  • 短信通知22名男性丙戊酸患者,仅1人回复,单独短信效果不佳
  • 电话成功联系18人,13人经电话获知MHRA指导,5人此前已知晓
  • 无患者因该干预开始避孕或寻求药师建议等额外行动

核心结论

  • 该项目提高了男性丙戊酸患者对家庭计划风险的文档记录和认知,但短信单独无效,个性化电话更成功。

研究设计与样本

  • 质量改进项目,使用EMIS识别22名使用丙戊酸的男性患者,发送Accurx短信并两次尝试电话随访。

主要发现

  • 全部22名患者收到短信,仅1人回复;电话成功联系18人,其中8人确认收到短信、10人未收到。
  • 5人已了解MHRA警示,13人在电话中获知;4人无法联系。
  • 无患者请求更多信息或采取开始避孕、寻求药师建议等额外行动。

关键数值与推荐

  • 目标为确保100%男性丙戊酸患者在2个月内获知MHRA家庭计划风险指导并接受有效避孕建议。

临床怎么用

  • 未来策略应包括常规药物审查、药师主导讨论和系统提醒,以确保持续患者教育。

局限性

  • 原文未报告样本量、P值等统计细节,且电话仅尝试两次,4人无法联系,可能影响干预覆盖完整性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Valproate, commonly used for epilepsy and bipolar disorder, carries known teratogenic risks when taken by women during pregnancy. In 2023, the Medicines and Healthcare products Regulatory Agency (MHRA) issued updated guidance suggesting a possible link between valproate use in males around conception and neurodevelopmental disorders in offspring. However, awareness among male patients and documentation of advice in general practice remains inconsistent. AIM: To ensure that 100% of male patients on valproate were informed of MHRA guidance regarding family planning risks and advised on effective contraception within a 2-month period. METHOD: Using EMIS, 22 male patients on valproate were identified. An Accurx text message was sent outlining MHRA guidance, contraception advice, and encouraging contact if planning a family. The text auto-coded advice into the EMIS record. Follow-up phone calls were made over two attempts to confirm receipt and provide verbal guidance where needed. RESULTS: All 22 patients received the text; only one responded. Phone contact was successful with 18 patients: eight confirmed receiving the text, and 10 had not. Five were already aware of the MHRA alert, while 13 were informed during calls. Four patients could not be contacted. No patients requested further information or took additional action such as starting contraception or seeking pharmacist advice. CONCLUSION: This quality improvement project improved documentation and patient awareness of valproate-associated family planning risks. Text messaging alone was ineffective; personalised phone calls were more successful. Future strategies should include routine medication reviews, pharmacist-led discussions, and system alerts to ensure ongoing patient education.

来源:Br J Gen Pract,查看原文。版权归原作者所有。

引用

  1. Shahul SF. Quality improvement project improving awareness of family planning risks with valproate in male patients. Br J Gen Pract. 2026. PMID: 42134936. doi:10.3399/bjgp26X745605

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。